Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from 12 to 13 directors through appointment of Dr. John M. Carethers.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 12 to 13 directors through appointment of Dr. John M. Carethers
- Carethers classified independent under NYSE and AbbVie governance standards, supporting board oversight credibility
- Appointment to Public Policy and Sustainability Committee adds healthcare and policy expertise
- Independent-director compensation governed by terms disclosed in AbbVie’s March 31, 2025 Form 10-Q exhibit
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.